A randomized controlled trial comparing 2% chlorhexidine and 3% sodium hypochlorite as root canal irrigants for pain resolution in patients with symptomatic irreversible pulpitis and apical periodontitis.

开始日期2026-03-02

申办/合作机构

Khyber Medical College

NCT07346326

/ RecruitingN/AIIT

Comparative Study of Functional Outcomes Between Peroneus Longus and Hamstring Tendon Autografts in Arthroscopic ACL Reconstruction: A Randomized Controlled Trial

This is a prospective, single-blinded, randomized controlled trial. Sixty patients (≥18 years) with an isolated ACL injury will be randomly assigned to receive an ACL reconstruction using either a Peroneus Longus Tendon (PLT) autograft or a Hamstring Tendon (HST) autograft. The primary objective is to compare early functional outcomes between the two groups at 6 weeks and 3 months post-surgery, using the Lysholm Knee Score. The study aims to demonstrate the non-inferiority of the PLT graft. All surgeries will be performed arthroscopically at Khyber Teaching Hospital, Peshawar, followed by a standardized rehabilitation protocol.

开始日期2026-01-01

申办/合作机构

Khyber Medical University

[+1]

NCT07119814

/ Not yet recruitingN/A

Comparison of Outcome of Safe T Separators and Conventional Elastomeric Separators

All participants in this study will be provided with information concerning the study's objectives, and benefits associated with participation. Participants will be informed that their involvement in this study presents no potential risks associated with their participation. Written consent will be obtained with appropriate information provided. Demographic data like age, BMI, gender, residence, socio economic status, occupation status, and literacy status will be documented. Patients undergoing fixed orthodontic treatment will be allocated in two groups equally by using the blocked randomization technique. Patients in Group A will undergo safe-T separators i.e initial thickness of Safe-T separators will be 1mm, Patients in Group B will undergo conventional elastomeric separators i.e thickness of elastomeric separators will be 1.2 mm. Separators will be positioned on either side of lower arch, each type of separator will be in sites, resulting in a sites within the lower arch. A separator placement tool will be utilised to position the separators. The comprehensive assessment will be carried out under the supervision of a consultant possessing at least five years of post-fellowship experience. Patient data will be recorded using a predefined structured proforma.

开始日期2025-12-01

申办/合作机构

Khyber Medical College

100 项与 Khyber Medical College 相关的临床结果

登录后查看更多信息

0 项与 Khyber Medical College 相关的专利（医药）

登录后查看更多信息

438

项与 Khyber Medical College 相关的文献（医药）

2026-04-01·Medicina de Familia-SEMERGEN

Demographic and regional trends in all-cause mortality among adults with coexisting multiple myeloma and cardiovascular disease in the United States, 1999–2023: A CDC WONDER analysis

Article

作者: Iftikhar, S ; Noor, R ; Asghar, T ; Akbar, S M A ; Qadri, M ; Ali, S ; Ahmad, B ; Prakash, V

INTRODUCTION:

Multiple myeloma (MM) frequently coexists with cardiovascular disease (CVD), contributing to elevated morbidity and mortality. Despite this correlation, national patterns in mortality among individuals with both MM and CVD remain understudied. This study examined demographic and regional trends in all-cause mortality among adults aged ≥35 with coexisting MM and CVD in the United States from 1999 to 2023.

METHODS:

Using ICD-10 Codes: C90.0 and I00-I79, we extracted data from the CDC-WONDER from 1999 to 2023. Crude mortality rates (CMRs) and age-adjusted mortality rates (AAMRs) per 100,000 population were calculated. Joinpoint regression analysis was utilized to evaluate annual percent change (APC) and average annual percent changes (AAPC).

RESULTS:

A total of 116,821 deaths were reported throughout the study period. Overall, there was a slight decline in AAMR due to MM and CVD with an AAPC of -0.05% (95% CI: -0.28 to 0.24). A notable rise in mortality was observed between 2018 and 2021, likely influenced by the COVID-19 pandemic. Stratified analyses showed persistent increase in mortality rates among men, older adults, non-Hispanic (NH) White individuals and residents of the West and small/medium metropolitan areas. Among cardiovascular subtypes, hypertensive disease exhibited the highest mortality rates and consistent upward trend.

CONCLUSION:

Although all-cause mortality from MM and CVD has slightly declined over the past two decades, significant disparities persist across demographic and geographic subgroups. Targeted efforts focused on cardiovascular risk assessment, preventive care, and equitable access to healthcare are urgently needed to reduce the burden of mortality in patients with coexisting MM and CVD in this vulnerable group.

2026-03-01·PEDIATRIC INFECTIOUS DISEASE JOURNAL

In Reply: Factors Predicting Readmission to the Emergency Department After a Diagnosis of Acute Respiratory Infection: A Two-year Experience at a Pediatric Tertiary Care Hospital in Italy

Article

作者: Shahzad, Tayyaba

2026-03-01·AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Clinical Outcomes and Safety Profile of Adagrasib in KRAS G12C-Mutated Solid Tumors

Article

作者: Alam, Umama ; Khan, Wajiha F. ; Banatwala, Umm E. Shabbar Salma ; Islam, M. Rafiqul ; Rath, Shree ; Sajjad, Fatima ; Ahmad, Osama ; Gain, Abbas M. ; Wahid, Abdul

Objectives::

KRAS G12C mutations are key oncogenic drivers in multiple solid tumors. Adagrasib, a selective KRAS G12C inhibitor, has demonstrated promising efficacy and safety in clinical studies. This single-arm meta-analysis comprehensively evaluates key clinical outcomes of Adagrasib, including survival benefits and adverse events, in patients with KRAS G12C-mutant solid tumors.

Methods::

Literature search was conducted across 4 databases to identify clinical trials and observational studies evaluating Adagrasib performance in patients with KRAS G12C-mutant solid tumors. A single-arm analysis was performed using the inverse variance method in the “meta” package of RStudio. Log Proportion and standardised mean difference (SMD) with a 95% CI were pooled using a random-effects model. Heterogeneity was assessed using I ² statistics.

Results::

Six studies involving 400 patients were included in our analysis. Adagrasib showed a median overall survival (OS) of 14.74 months (95% CI: 12.06-17.42, I ²=40.4%) and progression-free survival (PFS) of 6.80 months (95% CI: 6.14-7.46, I ²=0%), indicating significant survival benefits. The disease control rate (DCR) was 83%, reflecting robust tumor response and stabilization. Safety analysis revealed that 97% of patients experienced at least one adverse event of varying grades.

Conclusions::

Adagrasib demonstrated robust efficacy in KRAS G12C-mutant solid tumors, with significant survival benefits and high response rates. However, frequent adverse events and dose modifications, along with variability in response rates, highlight tolerability challenges. Further studies are needed to optimize dosing, improve patient selection, and explore combination strategies to enhance outcomes and minimize unwanted effects.

100 项与 Khyber Medical College 相关的药物交易

登录后查看更多信息

100 项与 Khyber Medical College 相关的转化医学

登录后查看更多信息